Trial ID or NCT#

NCT01657942

Status

not recruiting iconNOT RECRUITING

Purpose

The hypothesis of this study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for intermediate risk, organ-confined prostate lesions, with a low incidence of morbidity. The study hypothesis will be tested by measuring treatment-related safety and initial effectiveness parameters in the ExAblate MRgFUS treated patients, as described above.

Official Title

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

Eligibility Criteria

Ages Eligible for Study: Older than 50 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No

Investigator(s)

Geoffrey Sonn
Geoffrey Sonn
Urologic oncologist, Urologist, Urologic specialist, Genitourinary specialist
Assistant Professor of Urology and, by courtesy, of Radiology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Ccto
(650) 498-7061